The Guardant360® assay is a breakthrough liquid biopsy that provides fast, accurate and comprehensive genomic results from a simple blood draw in approximately seven days upon receipt in the laboratory. This liquid biopsy detects all four classes of genomic variations in 70+ genes most relevant to solid tumors and microsatellite instability-high. From the test results, physicians are able to see the most current genomic profile of a patient’s tumor and recommend appropriate treatment. This test has 90% agreement with tissue for targetable alterations, making this a feasible alternative to pick up actionable tumor mutations missed during tissue biopsies. Guardant Health's liquid biopsy, Guardant360® CDx is the first liquid biopsy to receive US FDA Approval for comprehensive tumor mutation profiling across all solid cancers. For Guardant Health Asia, Middle East and Africa (AMEA), this FDA approval represents a landmark achievement for the Guardant360 test that we offer in AMEA. Currently, the Guardant360 test is commercially available in 41 countries in AMEA. To order the test, visit us online at www.guardanthealthamea.com/request-a-kit/. If you have any queries, send us an email at clientservices@guardantamea.com or contact us on WhatsApp: +65 8940 0360.